Hovione
Hovione, established in 2015, is a Portugal-based pharmaceutical company specializing in the manufacturing of drug substances for off-patent and new drugs. It focuses on complex drug testing, molecule screening, and particle engineering to accelerate and enhance drug development, particularly in dermatology, ophthalmology, and respiratory fields. Hovione partners with pharmaceutical customers to complete clinical development, regulatory approval, and commercialization, aiming to make treatments faster and more affordable.
Top Stages
Past deals in Wales
SolasCure
Series A in 2021
SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on advancing treatment options for patients with chronic wounds. Founded in 2017, the company is developing Aurase, a hydrogel designed to enhance wound bed preparation through the application of a recombinant enzyme derived from maggots. This innovative approach aims to facilitate wound debridement, a crucial therapeutic procedure that removes dead, damaged, or infected tissue, thereby accelerating the healing process. By leveraging biomimicry and evidence-based medicine, SolasCure seeks to improve patient outcomes across various healthcare settings.
SolasCure
Seed Round in 2018
SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on advancing treatment options for patients with chronic wounds. Founded in 2017, the company is developing Aurase, a hydrogel designed to enhance wound bed preparation through the application of a recombinant enzyme derived from maggots. This innovative approach aims to facilitate wound debridement, a crucial therapeutic procedure that removes dead, damaged, or infected tissue, thereby accelerating the healing process. By leveraging biomimicry and evidence-based medicine, SolasCure seeks to improve patient outcomes across various healthcare settings.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.